{ "symbol": "EDIT", "company": "Editas Medicine, Inc.", "generated_at": "2026-06-24T07:36:47.417Z", "event_count": 6, "events": [ { "type": "pipeline_event", "ts": "2026-06-20T14:27:13.795Z", "stage": "scout", "outcome": "failed", "reason": null, "trigger": "[8k_recent] 1 recent 8-K(s) in last 7 days, latest filed 2026-06-18", "source": "hunter" }, { "type": "scout_dossier", "ts": "2026-06-13T18:49:53.601Z", "summary": "The investigation into Editas Medicine reveals that the Form 4 cluster trigger was not genuine open-market insider buying but rather mandatory tax-withholding sales from RSU vestings under pre-set 10b5-1 plans by three insiders (CEO, CFO, CSO) on June 3. These are NOT bullish signals. EDIT is a loss-making preclinical gene-editing biotech with ~$124M cash and an accumulated deficit of $1.65B burning roughly $23M/quarter in Q1 2026. The company raised $117M gross via a dilutive secondary offering (55.5M shares + warrants) on May 26, 2026. EDIT-401 shows strong (~90%) LDL-C/Lp(a)/ApoB reductions in NHPs with CTN filing targeted mid-2026 and early human proof-of-concept by end of 2026 — but this is entirely preclinical with no guarantee of clinical success. The stock has collapsed ~45% from its 52-week high, sits below both MAs, shows bearish technical momentum (RSI 40.9, MACD bearish cross). No credible mispricing edge exists given the binary risk profile and near-certain future dilution.", "verdict": "no_anomaly", "confidence": 5, "tool_calls": 21, "walltime_min": 32, "debug_path": "dossiers/2026-06-13-EDIT.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-06-06T03:30:39.003Z", "skip": true, "reason": "Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.", "score": 8, "breakdown": { "smart_money": 0, "options_flow": 0, "catalyst": 8, "mispricing": 0, "quality": 0, "technical": 0 }, "debug_path": "drafts/2026-06-06-EDIT.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-06T03:30:11.765Z", "summary": "EDIT is a cash-burning pre-clinical gene editing company that has raised ~$117M in a May 2026 equity offering (55.5M shares + warrants) days before this investigation was triggered. The Form 4 cluster — the stated trigger — consisted entirely of pre-arranged tax-withholding sales by three insiders (CEO, CFO, CSO), not open-market purchases. There are no genuine insider open-market buys in any recent window. EDIT-401 for hyperlipidemia is on track to file an IND mid-2026 with early human proof-of-concept data expected year-end 2026 — a real catalyst — but the stock is now heavily diluted post-offering and sitting near its post-offering low ($2.71 from ~$3.08 offer price). The options flow shows strong call-bias (95.6% net directional), but at micro-cap scale this reflects speculative interest, not institutional conviction. No asymmetric long setup exists given heavy dilution and the distance between current price ($2.71) and analyst target mean ($5.78). This warrants income-only consideration.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 18, "walltime_min": 21, "debug_path": "dossiers/2026-06-06-EDIT.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-26T16:29:50.745Z", "summary": "Editas is a pre-revenue CRISPR gene editing biotech that just completed a massive $319M public offering (55.5M new shares + warrants) in the same week it announced positive EDIT-401 preclinical data at EAS Congress showing ~90% LDL-C/Lp(a)/ApoB reductions in NHPs. The company is burning ~$23M/quarter with only $123M in cash, and the dilution — on top of prior ATM sales totaling 14.3M shares for $43.9M — massively expands the share count at a time when no product revenue exists. EDIT-401 remains preclinical with a CTN filing planned mid-2026; human proof-of-concept is 12+ months away. No insider open-market buys in 90 days, only option grants (CEO: 1.015M shares; CFO: 292K shares) as part of compensation packages. The stock is technically neutral to bearish with no smart-money clustering signal.", "verdict": "no_anomaly", "confidence": 5, "tool_calls": 22, "walltime_min": 15, "debug_path": "dossiers/2026-05-26-EDIT.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-15T23:05:40.949Z", "summary": "Editas Medicine is a pre-revenue CRISPR gene editing biotech whose lead program EDIT-401 showed compelling preclinical data (90%+ LDL-C reduction in NHPs at 6 months) presented at ASGCT on May 14. The company switched auditors from EY to PwC in April and recently reported Q1 results with narrowing losses (-$0.26 vs -$0.24 est). However, the stock is deeply unprofitable (negative FCF), trading near cash ($123M net cash vs $256M market cap), below both 50DMA and 200DMA, and has a dangerous ~18-month runway into Q3 2027 — insufficient for Phase I/II completion. The CEO received a large options grant (1M shares at $2.54) in March but no open-market insider purchases exist. IV is elevated (~115% ATM on June expiry). No asymmetric long or income setup is compelling given the binary clinical risk and near-term cash constraints.", "verdict": "no_anomaly", "confidence": 4, "tool_calls": 23, "walltime_min": 23, "debug_path": "dossiers/2026-05-15-EDIT.scout.debug.json" } ], "lessons": [], "chart_signal": { "ticker": "EDIT", "call": "HOLD", "confidence": 2, "score": 2, "factors": { "above_200dma": "+2", "below_50dma": "-1", "momentum_up": "+1 (18.7%)", "rsi_neutral": "0 (50.2)", "macd_above_signal": "+1", "recent_macd_bullish_cross": "+1 (0d ago)", "broken_below_high": "-2 (-33.5% from high)" }, "summary": "HOLD (score +2) · 12-1 mom 18.7% · RSI 50.2 · above_200_only · -33.5% from high", "last_close": 2.76, "one_month_ago_close": 2.67, "twelve_month_ago_close": 2.25, "twelve_one_momentum_pct": 18.67, "rsi_14": 50.2, "ma_stack": "above_200_only", "from_period_high_pct": -33.49, "period_high": 4.15, "price_targets": { "bear": 1, "fair": 3.83, "bull": 15, "bear_return_pct": -63.8, "fair_return_pct": 38.6, "bull_return_pct": 443.5, "method": "street_targets ⨯ chart_floors", "street": { "target_low": 1, "target_mean": 5.77778, "target_high": 15, "analyst_count": 9 } }, "generated_at": "2026-06-24T07:36:47.412Z" } }